Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study

JOURNAL OF THE NEUROLOGICAL SCIENCES

卷:415

Article

Bringeland, Gerd Haga^1,2  Myhr, Kjell-Morten^1,2  Vedeler, Christian Alexander^1,2  Gavasso, Sonia^1,2 

[1] Haukeland Hosp, Dept Neurol, Neuro SysMed, Bergen, Norway

[2] Univ Bergen, Dept Clin Med, Bergen, Norway

关键词: Relapsing-remitting multiple sclerosis;    Natalizumab;    Wearing-off;    Biomarkers;    Receptor occupancy;    Treatment response;   

DOI  :  10.1016/j.jns.2020.116880

来源: Elsevier

【 摘 要 】

Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by binding alpha 4 integrin and inhibiting leukocyte migration to the central nervous system. We recently reported an association between low natalizumab receptor occupancy and subjective wearing-off symptoms at the end of the 4-week dosing interval. Here, we aimed to evaluate the short-term risk of disease activity in a 1-year prospective follow-up of the same patient cohort (n = 40). We found that all patients available for follow-up after one year (n = 35) fulfilled the criteria for no evidence of disease activity (NEDA). Thus, wearing-off symptoms were not associated with increased short-term risk of disease activity. Longer follow-up in a larger patient cohort is required to establish whether therapeutic efficacy is maintained in patients with wearing-off symptoms.

【 授权许可】

Free